Drug Discovery World

MARCH 18, 2024

Targeted oral peptide JNJ-2113 maintained skin clearance in moderate-to-severe plaque psoriasis (PsO) through one year in the Phase 2b FRONTIER 2 clinical trial extension, Johnson & Johnson (J&J) has reported. JNJ-2113 is the first and only investigational targeted oral peptide designed to block the IL-23 receptor.

Dermatology 52

Dermatology Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 30, 2023

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation for FT011 for the treatment of systemic sclerosis (scleroderma).

Drug Trials 59

Drug Trials Trials Drugs Clinical Trials 59

Pharmaceutical Technology

JULY 12, 2022

Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in adult and adolescent patients. A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses. versus a vehicle rate of 6.1%

Dermatology 162

Dermatology Immune Response Trials Clinical Trials 162

Drug Discovery World

MARCH 13, 2024

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor. at 16 weeks and 76.2% at 52 weeks). .

Trials 52

Trials Dermatology Clinical Trials Clinical Trials 52

XTalks

AUGUST 2, 2023

Eichenfield was also the principal investigator on clinical trials evaluating YCANTH. Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases that require medical interventions.

Life Science 52

Life Science FDA Approval Dermatology Pharmacy 52

Pharmaceutical Technology

APRIL 17, 2023

The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. QPS was established in 1995 to provide bioanalytical LC-MS/MS contract services.

Dermatology 130

Dermatology Clinical Trials Clinical Trials Production 130

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. Clinical response was observed after just two weeks in some cases. A maintenance study showed the same effects at 52 weeks.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

Pharmaceutical Technology

MARCH 27, 2023

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

Medicine 246

Medicine Gene Therapy Gene Dermatology 246

XTalks

APRIL 17, 2023

In clinical trials, patients experienced significantly clearer skin and less interference with sleep due to itch when taking lebrikizumab compared to placebo. The ADvocate1 and ADvocate2 Phase III studies were published in the New England Journal of Medicine and the British Journal of Dermatology , respectively.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

pharmaphorum

MAY 14, 2021

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. But Reuters reported that the doctor identified as its principal clinical trial investigator has said he is not in charge of the trial.

Drug Trials 52

Drug Trials Trials Drugs Dermatology 52

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). According to GlobalData, Phase I drugs for Genital Warts (Condylomata Acuminata) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase I drugs for Cervical Intraepithelial Neoplasia (CIN) have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Drug Discovery World

DECEMBER 20, 2023

The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines. The post Clinical research business continues to expand in US appeared first on Drug Discovery World (DDW).

Clinical Research 52

Clinical Research Research Cardiology Dermatology 52

XTalks

JUNE 17, 2024

Hugel, a Korean medical aesthetics company, recently announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its botulinum toxin, Letybo (letibotulinumtoxinA-wlbg), for the treatment of glabellar lines. 134 How Does Letybo Work?

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

Drug Discovery World

DECEMBER 19, 2022

A double-blind, placebo-controlled clinical trial of a gene therapy gel developed at Stanford Medicine shows improved wound healing in 31 people with the disease, including 19 who were 18 years old or younger. . One trial participant was Vincenzo Mascoli, aged 22. Now he can bathe and sleep on his back without pain. “Now

Gene Therapy 52

Gene Therapy Gene Dermatology Clinical Trials 52

Drug Discovery World

SEPTEMBER 13, 2022

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s allosteric tyrosine kinase 2 inhibitor Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. The post FDA approves new first-line treatment for plaque psoriasis appeared first on Drug Discovery World (DDW).

FDA Approval 52

FDA Approval Dermatology Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 14, 2022

Used for both cosmetic and therapeutic cases, Botox is a US Food and Drug Administration (FDA)-approved injection of botulinum toxin, a neurotoxic protein that can effectively paralyze the facial muscles. Daxxify is effective, as safe as competitors, and has been well tolerated in clinical trials. A Novel Botox Competitor.

Botox 98

Botox FDA Approval Cosmetics Clinical Trials 98

XTalks

MAY 31, 2022

The spotlight for plaque psoriasis treatment is now on Vtama (tapinarof) cream (one percent), Dermavant’s discovery that has become the first steroid-free topical medication in its class approved by the US Food and Drug Administration (FDA). XTALKS WEBINAR: All Means All: The Road to Inclusivity in Clinical Trials.

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

Drug Discovery World

DECEMBER 16, 2022

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . First AML patient successfully transplanted with investigational drug . Experimental immunotherapy has over 70% response rate .

Drugs 52

Drugs Vaccination Vaccine Genetics 52

Drug Discovery World

DECEMBER 13, 2022

Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. . Clinical trial details.

Dermatology 52

Dermatology Clinical Trials Clinical Trials Antibody 52

The Pharma Data

MAY 15, 2023

Positive data from two Phase 3 Dupixent ® (dupilumab) trials in prurigo nodularis published in Nature Medicine Positive results from two Phase 3 Dupixent ® (dupilumab) trials in adults with uncontrolled prurigo nodularis have been published in Nature Medicine. Results from the trials were the basis for the U.S.

Medicine 40

Medicine Trials Dermatology FDA Approval 40

pharmaphorum

FEBRUARY 28, 2022

Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysis bullosa (EB). The post FDA turns down Amryt’s epidermolysis bullosa drug appeared first on. pic.twitter.com/NzhGx1q1o8.

Drugs 98

Drugs Marketing Regulation FDA Approval 98

XTalks

MARCH 24, 2023

The company recently presented a pooled analysis from clinical studies of their DermaSensor skin cancer detection device at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The results presented were from two of DermaSensor’s four clinical studies that were submitted to the US Food and Drug Administration (FDA).

Dermatology 97

Dermatology Clinical Trials Clinical Trials Sales 97

XTalks

MAY 23, 2024

Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. In fact, tools such as dermatoscopes, digital imaging systems and artificial intelligence (AI)-powered diagnostic tools have become integral to dermatological practice.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

Scienmag

OCTOBER 25, 2020

A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. The BRAF gene is involved in telling healthy cells when to grow and form new cells, […].

Trials 41

Trials Gene Drugs Clinical Trials 41

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. The shortages have been partly blamed on the off-label prescribing of the drugs for weight loss.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

XTalks

SEPTEMBER 22, 2022

On September 1, 2022, Boehringer Ingelheim Pharmaceuticals announced in a press release that the US Food and Drug Administration (FDA) approved Spevigo (spesolimab-sbzo) intravenous injections for GPP flares in adults. Clinical Trial Behind Spevigo. Waldman Department of Dermatology.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Dermatology 52

XTalks

JUNE 10, 2024

Sotyktu (deucravacitinib) is a one-of-its-kind oral medication approved by the US Food and Drug Administration (FDA) indicated to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The portrayal opened up the possibility of a life unhindered by the visible signs of psoriasis.

Immune Response 52

Immune Response Dermatology Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 16, 2024

With bimekizumab, the analyses showed that over 48 weeks, the majority of patients, ~7 out of 10, achieved IHS4-55,” said Professor Tzellos, Department of Dermatology, Nordland Hospital Trust, Bodø, Norway. The post Monoclonal antibody improves hidradenitis suppurativa by 55% appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Dermatology Drugs Clinical Trials 52

Drug Discovery World

FEBRUARY 5, 2024

Williams discussed the advantages of the company’s ‘disease agnostic’ small molecule degraders, and its success so far in translating results from preclinical to clinical tests in dermatology, inflammation and oncology indications.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

The Pharma Data

NOVEMBER 29, 2021

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis. Bristol Myers Squibb moment blazoned that theU.S.

Medicine 52

Medicine Drugs Dermatology Trials 52